Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Register for an Upcoming Event
Please join us for a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Professor H. Miles Prince, specialist haematologist and principal investigator of the PTX-100 study.
In the session, Steven and Professor Prince will discuss:
- The results of the PTX-100 phase 1b trial, which exhibited excellent safety profile with no serious adverse events
- How the trial demonstrated a clinical signal seen in T cell lymphoma (TCL) patients
- PTX-100 will now progress to an expansion cohort study focussing on TCL with potential for subsequent registration study
This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.
Book Your Spot
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.
FEATURE SPEAKER
Steven Yatomi Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.
Professor H. Miles Prince
Specialist Haematologist
Professor Prince is an internationally recognised haematologist; a brilliant mind in the field of blood-related conditions, stem cell research and the study of the immune system – specifically in blood and cancer growth. He is the Director of the Centre for Blood Cell Therapy at Peter MacCallum Cancer Centre and Chairman of the Medical Scientific Advisory Committee to the Myeloma Foundation Australia, amongst other notable roles.